Published in AIDS on January 01, 1990
Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science (1999) 7.66
Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science (1997) 5.55
Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med (1998) 5.08
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis (1995) 4.60
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med (2001) 3.74
Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med (1990) 3.61
Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest (1988) 3.59
Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed) (1986) 3.27
Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus. Br Med J (Clin Res Ed) (1986) 2.75
Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci U S A (1998) 2.39
Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS (1998) 2.19
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS (2000) 2.14
The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS (1992) 2.06
[Therapeutic options for HIV infection should lead to increased utilization of HIV tests]. Ned Tijdschr Geneeskd (1999) 2.01
Gastric outlet obstruction and Helicobacter pylori. Am J Gastroenterol (1997) 1.99
Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol (1996) 1.80
Prevalence of Campylobacter-associated diarrhea among patients infected with human immunodeficiency virus. Clin Infect Dis (1997) 1.80
Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2000) 1.68
Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS (1999) 1.64
Effects of protease inhibitors on the course of CMV retinitis in relation to CD4+ lymphocyte responses in HIV+ patients. Br J Ophthalmol (1998) 1.57
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS (2000) 1.56
Validation of a new, commercially available dry rapid urease test for the diagnosis of Helicobacter pylori infection in gastric biopsies. Neth J Med (2006) 1.45
Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ (1989) 1.39
[Virological evaluation of treating HIV-infected patients with (combinations of) antiretroviral drugs at the Amsterdam Academic Medical Center, 1996/'97]. Ned Tijdschr Geneeskd (1998) 1.39
Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis (1999) 1.32
Duodenal stenosis does regress after eradication of Helicobacter pylori! J Clin Gastroenterol (1998) 1.29
Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis (1999) 1.28
Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands. Eur J Clin Microbiol Infect Dis (1996) 1.26
Subdural hematoma after lumbar puncture: two case reports and review of the literature. Clin Neurol Neurosurg (1991) 1.25
Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut (2000) 1.24
Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses. AIDS Res Hum Retroviruses (2001) 1.22
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS (1998) 1.21
A context-learning pharmacotherapy program for preclinical medical students leads to more rational drug prescribing during their clinical clerkship in internal medicine. Clin Pharmacol Ther (2008) 1.21
Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy. Proc Natl Acad Sci U S A (2000) 1.20
Comparison of three commercially available enzyme-linked immunosorbent assays and biopsy-dependent diagnosis for detecting Helicobacter pylori infection. J Clin Microbiol (1996) 1.18
Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group. AIDS (2000) 1.18
Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet (1988) 1.17
Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection. Proc Natl Acad Sci U S A (1999) 1.16
Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine. AIDS (2000) 1.16
Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis (1999) 1.13
QUOTE-HIV: an instrument for assessing quality of HIV care from the patients' perspective. Qual Saf Health Care (2003) 1.12
Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1999) 1.08
Foscarnet and penile ulceration. Lancet (1990) 1.04
Failure to maintain high-dose treatment regimens during long-term use of zidovudine in patients with symptomatic human immunodeficiency virus type 1 infection. Genitourin Med (1990) 1.04
Antigen-specific T-lymphocyte proliferative responses during highly active antiretroviral therapy (HAART) of HIV-1 infection. Immunol Lett (1999) 1.02
Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. AIDS (2001) 1.01
Serological and polymerase chain reaction-based analysis of aqueous humour samples in patients with AIDS and necrotizing retinitis. AIDS (1996) 1.01
Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis (2000) 1.00
The only good Helicobacter pylori is a dead Helicobacter pylori. Lancet (1997) 1.00
Antibody response to viral proteins U (vpu) and R (vpr) in HIV-1-infected individuals. J Acquir Immune Defic Syndr (1990) 0.99
Pathogenesis of HIV and its implications for serodiagnosis and monitoring of antiviral therapy. J Virol Methods (1987) 0.99
Autoimmunity against blood cells in human immunodeficiency-virus (HIV) infection. Br J Haematol (1987) 0.99
Echocardiographic dimensions and maximal oxygen uptake in oarsmen during training. Br Heart J (1981) 0.95
High-dose interferon-alpha2a exerts potent activity against human immunodeficiency virus type 1 not associated with antitumor activity in subjects with Kaposi's sarcoma. J Infect Dis (1997) 0.95
Diarrhoea in HIV-infected patients: no evidence of cytokine-mediated inflammation in jejunal mucosa. AIDS (1995) 0.92
Glomerular lesions and opportunistic infections of the kidney in AIDS: an autopsy study of 47 cases. Adv Exp Med Biol (1989) 0.92
Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS (2000) 0.92
Halitosis and Helicobacter pylori infection. J Breath Res (2012) 0.91
Resumption of HIV antigen production during continuous zidovudine treatment. Lancet (1988) 0.91
Seven-day PPI-triple therapy with levofloxacin is very effective for Helicobacter pylori eradication. Neth J Med (2009) 0.90
Anorectal surgery in human immunodeficiency virus-infected patients. Clinical outcome in relation to immune status. Dis Colon Rectum (1995) 0.90
Eradication of Helicobacter pylori restores glutathione S-transferase activity and glutathione levels in antral mucosa. Jpn J Cancer Res (2001) 0.89
Serodiagnosis of Helicobacter pylori infection: an evaluation of a commercially available ELISA-IgG. Neth J Med (1995) 0.88
Persistence of human immunodeficiency virus antigenemia in patients with the acquired immunodeficiency syndrome treated with a reverse transcriptase inhibitor, suramin. Ten-patient case-control study. Arch Intern Med (1988) 0.88
Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 0.88
Mycobacterium xenopi in HIV-infected patients: an emerging pathogen. AIDS (1998) 0.87
Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs. AIDS Res Hum Retroviruses (2001) 0.86
Cellular and humoral immunity in various cohorts of male homosexuals in relation to infection with human immunodeficiency virus. Neth J Med (1989) 0.86
Otorhinolaryngological findings in AIDS patients: a study of 63 cases. Arch Otorhinolaryngol (1987) 0.86
Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations. AIDS Res Hum Retroviruses (2000) 0.86
Local excision and mucosal advancement for anorectal ulceration in patients infected with human immunodeficiency virus. Br J Surg (1995) 0.86
HIV seropositivity and tuberculosis in a large general hospital in Malawi. Trop Geogr Med (1990) 0.85
Costs and benefits of a test-and-treat strategy in Helicobacter pylori-infected subjects: a prospective intervention study in general practice. Eur J Gastroenterol Hepatol (2000) 0.84
Low antigenicity of HIV-1 rev: rev-specific antibody response of limited value as correlate of rev gene expression and disease progression. AIDS Res Hum Retroviruses (1989) 0.84
Helicobacter pylori antibiotic resistance in a Dutch region: trends over time. Neth J Med (2006) 0.83
Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir. AIDS (2000) 0.83
Diagnostic performance of biopsy-based methods for determination of Helicobacter pylori infection without a reference standard. J Clin Epidemiol (2000) 0.82
The importance of corpus biopsies for the determination of Helicobacter pylori infection. Neth J Med (2005) 0.82
Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine. AIDS (1988) 0.82
Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication. Aliment Pharmacol Ther (2005) 0.81
Results of long-term follow-up of HIV-infected patients treated with lamivudine monotherapy, followed by a combination of lamivudine and zidovudine. Antivir Ther (1997) 0.81
[The acquired immunodeficiency syndrome (AIDS)]. Ned Tijdschr Geneeskd (1983) 0.81
Common health problems in HIV-infected travelers to the (sub)tropics. J Travel Med (1999) 0.81
AIDS dementia complex and didanosine. Lancet (1994) 0.80
Amprolium for coccidiosis in AIDS. Lancet (1984) 0.80
Antiretroviral treatment: state of the art and future directions. AIDS (1991) 0.80
No beneficial effect of interferon-gamma treatment in 2 human immunodeficiency virus-infected patients with Mycobacterium avium complex infection. Clin Infect Dis (2001) 0.80
Determination of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) in biological fluids by reverse-phase high pressure liquid chromatography. Pharm Weekbl Sci (1987) 0.80
Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections. Antiviral Res (1998) 0.80
Prediction of infarct size from serial CK determinations: evaluation by clinical studies and computer simulation. Clin Chim Acta (1979) 0.80
90% cure: which anti-Helicobacter therapy can achieve this treatment goal? Am J Gastroenterol (1995) 0.80
T-cell progenitor function during progressive human immunodeficiency virus-1 infection and after antiretroviral therapy. Blood (2000) 0.80
Impact of diarrhoea and faecal incontinence on the daily life of HIV-infected patients. AIDS Care (1998) 0.79
General operative aspects of human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Am Coll Surg (1995) 0.79